Abstract:
A method of scheduling the transmission of cells from a network node involves storing entries in a schedule table at predetermined locations, wherein each location represents a point in time at which a cell is to be transmitted. Each entry in the table contains a pointer to a list of virtual circuits having cells scheduled for transmission at the time corresponding to the location of the entry in the table. When a VC has a cell to be transmitted at a particular time, the VC is queued to the head, rather than the tail, of the list of VCs pointed to by the pointer located at the entry in the table corresponding to the time at which the cell is to be transmitted. The VC is therefore the first VC transmitted from the list of VCs.
Abstract:
An apparatus and method for scheduling data transfers between a host and adapter. A schedule table data structure resides in a memory on the adapter. Each location in the schedule table represents a point in time at which data is to be transmitted from the adapter. A current time counter advances at the rate at which data is to be transmitted from the node. A pointer points to successive locations in the schedule table, and advances through the schedule table at a rate faster than the current time counter advances so that the value stored in the pointer represents a point in time which is ahead of the point in time currently represented by the value output from the current time counter. A request for a data transfer between the host and adapter is generated when a valid entry exists at the location pointed to by the pointer. The value of the pointer at the time the request is generated is stored as the last valid time. When a new entry is to be stored in the schedule table, it is stored at a location in the schedule table immediately after the location corresponding to the last valid time, and the pointer is reset to point to the location immediately after the location corresponding to the last valid time.
Abstract:
The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Abstract:
One embodiment of the present invention provides a switch. The switch includes a forwarding mechanism and a control mechanism. During operation, the forwarding mechanism forwards frames based on their Ethernet headers. The control mechanism operates the switch in conjunction with a separate physical switch as a single logical switch and assigns a virtual switch identifier to the logical switch, wherein the virtual switch identifier is associated with a link aggregation group.
Abstract:
Systems and techniques for processing and forwarding packets are described. Some embodiments provide a system (e.g., a switch) which determines an internal virtual network identifier and/or an internal policy identifier for a packet based on a port on which the packet was received and/or one or more fields in the packet. The system can then process and forward the packet based on the internal virtual network identifier and/or internal policy identifier. In some embodiments, the system encapsulates the packet in a TRILL (Transparent Interconnection of Lots of Links) packet by adding a TRILL header to the packet. In some embodiments, the scope of an internal virtual network identifier and/or an internal policy identifier may not extend beyond a switch or a module within a switch.
Abstract:
An interconnect switch stores data messages received from one or more source devices and prioritizes the data messages received from each source device based on the order that the data messages were received from the source device. For each available destination device associated with the interconnect switch, the interconnect switch identifies the data messages with the highest priority that are to be routed to the available destination device and selects one of the identified data messages for the available destination device. The interconnect switch then routes the selected data messages to the available destination devices.
Abstract:
The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.
Abstract:
A mist delivery system includes an enclosure having at least one misting nozzle coupled thereto. The enclosure includes a primary wall and a secondary wall, whereby an air channel is defined between the primary wall and the secondary wall. A controller directs misted air through the misting nozzle and further activates an air flow system such that misted air within the shower area flows through and is dried in the air channel.
Abstract:
The present invention is directed to sustained-release pharmaceutical formulations of therapeutic proteins containing carboxymethyl ether cellulose polymer and methods of manufacture and use thereof.
Abstract:
The invention is directed to compounds of Formulae I and II: wherein R1, R2, R3, R5, R6, Y1, Y2, Y3, Y4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.